Prediction of clinical drug-drug interactions of veliparib (ABT-888) with human renal transporters (OAT1, OAT3, OCT2, MATE1, and MATE2K)

Journal of Pharmaceutical Sciences

Volumn 102, Issue 12, 2013, Pages 4426-4432

  Kikuchi, Ryota ^a   Lao, Yanbin ^a   Bow, Daniel A J ^a   Chiou, William J ^a   Andracki, Mark E ^a   Carr, Robert A ^a   Voorman, Richard L ^a   De Morais, Sonia M ^a  

^a ABBVIE INC   (United States)

Author keywords

drug interaction; drug transport; membrane transporters; organic anion transporters; organic cation transporters; renal clearance; renal transport; veliparib

Indexed keywords

CARRIER PROTEIN; MATE1 PROTEIN; MATE2K PROTEIN; OAT1 PROTEIN; OAT3 PROTEIN; OCTAMER TRANSCRIPTION FACTOR 2; ORGANIC CATION TRANSPORTER; UNCLASSIFIED DRUG; VELIPARIB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG PROTEIN BINDING; EMBRYO; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; KIDNEY CLEARANCE; KNOCKOUT MOUSE; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; SINGLE DRUG DOSE; WILD TYPE;

DRUG INTERACTION; DRUG TRANSPORT; MEMBRANE TRANSPORTERS; ORGANIC ANION TRANSPORTERS; ORGANIC CATION TRANSPORTERS; RENAL CLEARANCE; RENAL TRANSPORT; VELIPARIB;

ANIMALS; BENZIMIDAZOLES; CELL LINE; HUMANS; KIDNEY; MICE; MICE, KNOCKOUT; MODELS, BIOLOGICAL; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; ORGANIC CATION TRANSPORT PROTEINS;

EID: 84888205222     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23737     Document Type: Article

References (40)

1. Xu J, Kochanek KD, Murphy SL, Tejada-Vera B,. 2010. Deaths: Final data for 2007. Natl Vital Stat Rep 58 (19): 1-134.
2. Ame JC, Spenlehauer C, de Murcia G,. 2004. The PARP superfamily. Bioessays 26 (8): 882-893.
3. Papeo G, Forte B, Orsini P, Perrera C, Posteri H, Scolaro A, Montagnoli A,. 2009. Poly(ADP-ribose) polymerase inhibition in cancer therapy: Are we close to maturity? Expert Opin Ther Pat 19 (10): 1377-1400.
4. Jagtap P, Szabo C,. 2005. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov 4 (5): 421-440.
5. Tentori L, Graziani G,. 2005. Chemopotentiation by PARP inhibitors in cancer therapy. Pharmacol Res 52 (1): 25-33.
6. Plummer ER,. 2006. Inhibition of poly(ADP-ribose) polymerase in cancer. Curr Opin Pharmacol 6 (4): 364-368.
7. Donawho CK, Luo Y, Penning TD, Bauch JL, Bouska JJ, Bontcheva-Diaz VD, Cox BF, DeWeese TL, Dillehay LE, Ferguson DC, Ghoreishi-Haack NS, Grimm DR, Guan R, Han EK, Holley-Shanks RR, Hristov B, Idler KB, Jarvis K, Johnson EF, Kleinberg LR, Klinghofer V, Lasko LM, Liu X, Marsh KC, McGonigal TP, Meulbroek JA, Olson AM, Palma JP, Rodriguez LE, Shi Y, Stavropoulos JA, Tsurutani AC, Zhu GD, Rosenberg SH, Giranda VL, Frost DJ,. 2007. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 13 (9): 2728-2737.
8. Palma JP, Wang YC, Rodriguez LE, Montgomery D, Ellis PA, Bukofzer G, Niquette A, Liu X, Shi Y, Lasko L, Zhu GD, Penning TD, Giranda VL, Rosenberg SH, Frost DJ, Donawho CK,. 2009. ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors. Clin Cancer Res 15 (23): 7277-7290.
9. Penning TD, Zhu GD, Gandhi VB, Gong J, Liu X, Shi Y, Klinghofer V, Johnson EF, Donawho CK, Frost DJ, Bontcheva-Diaz V, Bouska JJ, Osterling DJ, Olson AM, Marsh KC, Luo Y, Giranda VL,. 2009. Discovery of the poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4- carboxamide (ABT-888) for the treatment of cancer. J Med Chem 52 (2): 514-523.
10. Kummar S, Kinders R, Gutierrez ME, Rubinstein L, Parchment RE, Phillips LR, Ji J, Monks A, Low JA, Chen A, Murgo AJ, Collins J, Steinberg SM, Eliopoulos H, Giranda VL, Gordon G, Helman L, Wiltrout R, Tomaszewski JE, Doroshow JH,. 2009. Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol 27 (16): 2705-2711.
11. Muscal JA, Thompson PA, Giranda VL, Dayton BD, Bauch J, Horton T, McGuffey L, Nuchtern JG, Dauser RC, Gibson BW, Blaney SM, Su JM,. 2010. Plasma and cerebrospinal fluid pharmacokinetics of ABT-888 after oral administration in non-human primates. Cancer Chemother Pharmacol 65 (3): 419-425.
12. Davies B, Morris T,. 1993. Physiological parameters in laboratory animals and humans. Pharm Res 10 (7): 1093-1095.
13. Parise RA, Shawaqfeh M, Egorin MJ, Beumer JH,. 2008. Liquid chromatography-mass spectrometric assay for the quantitation in human plasma of ABT-888, an orally available, small molecule inhibitor of poly(ADP-ribose) polymerase. J Chromatogr B Analyt Technol Biomed Life Sci 872 (1-2): 141-147.
14. Wiegand R, Wu J, Sha X, LoRusso P, Li J,. 2010. Simultaneous determination of ABT-888, a poly (ADP-ribose) polymerase inhibitor, and its metabolite in human plasma by liquid chromatography/tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 878 (3-4): 333-339.
15. Inui KI, Masuda S, Saito H,. 2000. Cellular and molecular aspects of drug transport in the kidney. Kidney Int 58 (3): 944-958.
16. El-Sheikh AA, Masereeuw R, Russel FG,. 2008. Mechanisms of renal anionic drug transport. Eur J Pharmacol 585 (2-3): 245-255.
17. Kusuhara H, Sugiyama Y,. 2009. In vitro-in vivo extrapolation of transporter-mediated clearance in the liver and kidney. Drug Metab Pharmacokinet 24 (1): 37-52.
18. Li M, Anderson GD, Wang J,. 2006. Drug-drug interactions involving membrane transporters in the human kidney. Expert Opin Drug Metab Toxicol 2 (4): 505-532.
19. Masereeuw R, Russel FG,. 2010. Therapeutic implications of renal anionic drug transporters. Pharmacol Ther 126 (2): 200-216.
20. Fujita T, Urban TJ, Leabman MK, Fujita K, Giacomini KM,. 2006. Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variants. J Pharm Sci 95 (1): 25-36.
21. Koepsell H, Lips K, Volk C,. 2007. Polyspecific organic cation transporters: Structure, function, physiological roles, and biopharmaceutical implications. Pharm Res 24 (7): 1227-1251.
22. Hillgren KM, Keppler D, Zur A, Giacomini KM, Stieger B, Cass CE, Zhang L,. 2013. Emerging transporters of clinical importance: An update from the international transporter consortium. Clin Pharmacol Ther 94 (1): 52-63.
23. Cundy KC,. 1999. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin Pharmacokinet 36 (2): 127-143.
24. Ho ES, Lin DC, Mendel DB, Cihlar T,. 2000. Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J Am Soc Nephrol 11 (3): 383-393.
25. Nozaki Y, Kusuhara H, Kondo T, Iwaki M, Shiroyanagi Y, Nakayama H, Horita S, Nakazawa H, Okano T, Sugiyama Y,. 2007. Species difference in the inhibitory effect of nonsteroidal anti-inflammatory drugs on the uptake of methotrexate by human kidney slices. J Pharmacol Exp Ther 322 (3): 1162-1170.
26. Wang ZJ, Yin OQ, Tomlinson B, Chow MS,. 2008. OCT2 polymorphisms and in-vivo renal functional consequence: Studies with metformin and cimetidine. Pharmacogenet Genomics 18 (7): 637-645.
27. Song IS, Shin HJ, Shim EJ, Jung IS, Kim WY, Shon JH, Shin JG,. 2008. Genetic variants of the organic cation transporter 2 influence the disposition of metformin. Clin Pharmacol Ther 84 (5): 559-562.
28. Chen Y, Li S, Brown C, Cheatham S, Castro RA, Leabman MK, Urban TJ, Chen L, Yee SW, Choi JH, Huang Y, Brett CM, Burchard EG, Giacomini KM,. 2009. Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. Pharmacogenet Genomics 19 (7): 497-504.
29. Terada T, Inui K,. 2008. Physiological and pharmacokinetic roles of H+/organic cation antiporters (MATE/SLC47A). Biochem Pharmacol 75 (9): 1689-1696.
30. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L,. 2010. Membrane transporters in drug development. Nat Rev Drug Discov 9 (3): 215-236.
31. Tanihara Y, Masuda S, Sato T, Katsura T, Ogawa O, Inui K,. 2007. Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol 74 (2): 359-371.
32. Umehara KI, Iwatsubo T, Noguchi K, Kamimura H,. 2007. Comparison of the kinetic characteristics of inhibitory effects exerted by biguanides and H2-blockers on human and rat organic cation transporter-mediated transport: Insight into the development of drug candidates. Xenobiotica 37 (6): 618-634.
33. Tahara H, Shono M, Kusuhara H, Kinoshita H, Fuse E, Takadate A, Otagiri M, Sugiyama Y,. 2005. Molecular cloning and functional analyses of OAT1 and OAT3 from cynomolgus monkey kidney. Pharm Res 22 (4): 647-660.
34. Zolk O, Solbach TF, Konig J, Fromm MF,. 2009. Structural determinants of inhibitor interaction with the human organic cation transporter OCT2 (SLC22A2). Naunyn Schmiedebergs Arch Pharmacol 379 (4): 337-348.
35. Ito S, Kusuhara H, Kuroiwa Y, Wu C, Moriyama Y, Inoue K, Kondo T, Yuasa H, Nakayama H, Horita S, Sugiyama Y,. 2010. Potent and specific inhibition of mMate1-mediated efflux of type I organic cations in the liver and kidney by pyrimethamine. J Pharmacol Exp Ther 333 (1): 341-350.
36. Tweedie D, Polli JW, Berglund EG, Huang SM, Zhang L, Poirier A, Chu X, Feng B,. 2013. Transporter studies in drug development: Experience to date and follow-up on decision trees from the International Transporter Consortium. Clin Pharmacol Ther 94 (1): 113-125.
37. European Medicines Agency. Guideline on the Investigation of Drug Interactions. Accessed, at: http://www.ema.europa.eu/docs/en-GB/document- library/Scientific-guideline/2012/07/WC500129606.pdf last accessed on September 20th, 2013.
38. Li X, Delzer J, Voorman R, de Morais SM, Lao Y,. 2011. Disposition and drug-drug interaction potential of veliparib (ABT-888), a novel and potent inhibitor of poly(ADP-ribose) polymerase. Drug Metab Dispos 39 (7): 1161-1169.
39. Faessel HM, Obach RS, Rollema H, Ravva P, Williams KE, Burstein AH,. 2010. A review of the clinical pharmacokinetics and pharmacodynamics of varenicline for smoking cessation. Clin Pharmacokinet 49 (12): 799-816.
40. Feng B, Obach RS, Burstein AH, Clark DJ, de Morais SM, Faessel HM,. 2008. Effect of human renal cationic transporter inhibition on the pharmacokinetics of varenicline, a new therapy for smoking cessation: An in vitro-in vivo study. Clin Pharmacol Ther 83 (4): 567-576.